Blick G, Henry K, Greiger P, Kaplan S, Prasad B, Carey Z, Sasse R, Garton T, Hatton E, Groth K, Runne W, Kelly T, Sachs G, McCartney D, Westerbeck T; International Conference on AIDS.

Int Conf AIDS. 2000 Jul 9-14; 13: abstract no. TuPeB3191.

G. Blick, Blick Medical Associates, 589 Bedford Street, Stamford, CT 06901, United States, Tel.: +1 203 357 7800, Fax: +1 203 357 7841, E-mail: blickmd@aol.com

Background: Hepatitis C virus (HCV) has coinfected over 30% of individuals with HIV in the U.S. We are evaluating EWBH in individuals with HIV/AIDS failing antiretroviral therapy (ART). HIV is a heat-labile virus, and EWBH has been shown to be safe in individuals with HIV/AIDS. We report the results of the first known HIV/HCV coinfected patient to be treated with EWBH. Materials and Methods: This Phase II randomized, controlled trial is evaluating EWBH in 40 HIV/AIDS patients who are failing ART. EWBH is performed using the PS-1 Temet device from First Circle Medical via percutaneous cannulation of bilateral femoral veins. Core body temperature is raised over 60-120 minutes to 41.6-42.0C and maintained for a treatment period of 90 minutes. Results: A 43 yo male contracted HIV and HCV by IVDU. HIV was diagnosed in 1987, and chronic HCV was confirmed in 1993, and liver histology revealed piece-meal necrosis and a METAVIR score of F2. After failing 6 months of interferon in 1993, he began ART therapy in December 1993. Through 1999, he experienced virologic failure of nine 3-6 drug ART regimens. He was diagnosed with AIDS with a CD4 of 196 cells/mm3 in 1998. At baseline, he was taking a 6-drug regimen with an HIV RNA PCR 60,961 (log 4.79), HCV bDNA 14.3 MEq/ml (log 7.16), CD4% 20 and CD4# 108. He stopped HAART and underwent a single session of EWBH without complication. At Day 3, HCV bDNA was 38.3 MEq/ml (log 7.58) and HIV RNA PCR 100,641 (log 5.0). HCV bDNA continued to decline as follows: 8.38 MEq/ml (log 6.92) at week 3, 5.26 (log 6.72) at week 4, 1.36 (log 6.13) at week 8, 0.65 (log 5.81) at week 10, and undetectable >0.2 (>log 5.30) at weeks 12 and 16. Conclusions: We report the first case demonstrating reduction of HCV viremia by almost 2 logs to undetectable levels by weeks 12 and 16 following a single session of EWBH at 41.6-42.0C for 90 minutes in an HIV/HCV coinfected patient. Further evaluation is warranted.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Anti-HIV Agents
• Antiretroviral Therapy, Highly Active
• Drug Therapy, Combination
• HIV
• HIV Infections
• HIV Protease Inhibitors
• HIV Seropositivity
• Hepacivirus
• Hepatitis C
• Humans
• Interferon Alfa-2b
• Male
• United States
• Viremia
• drug therapy
• therapy

Other ID:

• GWAIDS0001610

UI: 102239101

From Meeting Abstracts